| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Appili Therapeutics Inc (OTCQX: APLIF)
APLIF Technical Analysis
1.5
| As on 14th Jan 2025 APLIF STOCK Price closed @ 0.03 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.03 & Sell for SHORT-TERM with Stoploss of 0.03 we also expect STOCK to react on Following IMPORTANT LEVELS. |
APLIFSTOCK Price
| Open | 0.03 | Change | Price | % |
| High | 0.03 | 1 Day | 0.01 | 50.00 |
| Low | 0.03 | 1 Week | 0.01 | 50.00 |
| Close | 0.03 | 1 Month | 0.01 | 50.00 |
| Volume | 10000 | 1 Year | 0.01 | 50.00 |
| 52 Week High 0.05 | 52 Week Low 0.01 | ||||
OTCQX USA Most Active Stocks
| KRRGF | 4.83 | 2.33% |
| FCUUF | 0.52 | -20.00% |
| ETHE | 27.50 | -3.34% |
| CURLF | 2.04 | 22.89% |
| VRNOF | 1.90 | 24.18% |
| GBTC | 76.47 | 3.11% |
| AOTVF | 0.14 | -6.67% |
| CRLBF | 1.26 | 21.15% |
| TCNNF | 6.48 | 16.55% |
| EMHTF | 0.04 | 33.33% |
OTCQX USA Top Gainers Stocks
OTCQX USA Top Losers Stocks
| APLIF Daily Charts |
APLIF Intraday Charts |
Whats New @ Bazaartrend |
APLIF Free Analysis |
|
|
APLIF Important Levels Intraday
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
APLIF Forecast January 2025
| 4th UP Forecast | 0.15 |
| 3rd UP Forecast | 0.11 |
| 2nd UP Forecast | 0.09 |
| 1st UP Forecast | 0.06 |
| 1st DOWN Forecast | -0 |
| 2nd DOWN Forecast | -0.03 |
| 3rd DOWN Forecast | -0.05 |
| 4th DOWN Forecast | -0.09 |
APLIF Weekly Forecast
| 4th UP Forecast | 0.03 |
| 3rd UP Forecast | 0.03 |
| 2nd UP Forecast | 0.03 |
| 1st UP Forecast | 0.03 |
| 1st DOWN Forecast | 0.03 |
| 2nd DOWN Forecast | 0.03 |
| 3rd DOWN Forecast | 0.03 |
| 4th DOWN Forecast | 0.03 |
APLIF Forecast2025
| 4th UP Forecast | 0.16 |
| 3rd UP Forecast | 0.12 |
| 2nd UP Forecast | 0.09 |
| 1st UP Forecast | 0.07 |
| 1st DOWN Forecast | -0.01 |
| 2nd DOWN Forecast | -0.03 |
| 3rd DOWN Forecast | -0.06 |
| 4th DOWN Forecast | -0.1 |
Appili Therapeutics Inc ( OTCQX USA Symbol : APLIF )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
APLIF Business Profile
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada. Address: #21-1344 Summer Street, Halifax, NS, Canada, B3H 0A8
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service